252 related articles for article (PubMed ID: 33553512)
1. Alendronate and omeprazole in combination reduce angiogenic and growth signals from osteoblasts.
Krüger TB; Herlofson BB; Lian AM; Syversen U; Reseland JE
Bone Rep; 2021 Jun; 14():100750. PubMed ID: 33553512
[TBL] [Abstract][Full Text] [Related]
2. Alendronate alters osteoblast activities.
Krüger TB; Herlofson BB; Landin MA; Reseland JE
Acta Odontol Scand; 2016 Oct; 74(7):550-557. PubMed ID: 27546224
[TBL] [Abstract][Full Text] [Related]
3. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model.
Komatsu K; Shimada A; Shibata T; Wada S; Ideno H; Nakashima K; Amizuka N; Noda M; Nifuji A
J Endocrinol; 2013 Nov; 219(2):145-58. PubMed ID: 24096963
[TBL] [Abstract][Full Text] [Related]
4. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Ishtiaq S; Edwards S; Sankaralingam A; Evans BA; Elford C; Frost ML; Fogelman I; Hampson G
Cytokine; 2015 Feb; 71(2):154-60. PubMed ID: 25461393
[TBL] [Abstract][Full Text] [Related]
5. Effects of alendronate and pamidronate on apoptosis and cell proliferation in cultured primary human gingival fibroblasts.
Soydan SS; Araz K; Senel FV; Yurtcu E; Helvacioglu F; Dagdeviren A; Tekindal MA; Sahin F
Hum Exp Toxicol; 2015 Nov; 34(11):1073-82. PubMed ID: 25636638
[TBL] [Abstract][Full Text] [Related]
6. Targeting a therapeutically relevant concentration of alendronate for in vitro studies on osteoblasts.
Krüger TB; Syversen U; Herlofson BB; Lian AM; Reseland JE
Acta Odontol Scand; 2022 Nov; 80(8):619-625. PubMed ID: 35605138
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells.
Zhang J; Park J; Lee JW; Kwon YD; Kim EC
Clin Oral Investig; 2018 Jun; 22(5):1933-1943. PubMed ID: 29188452
[TBL] [Abstract][Full Text] [Related]
8. Study on in vitro release and cell response to alendronate sodium-loaded ultrahigh molecular weight polyethylene loaded with alendronate sodium wear particles to treat the particles-induced osteolysis.
Qu S; Bai Y; Liu X; Fu R; Duan K; Weng J
J Biomed Mater Res A; 2013 Feb; 101(2):394-403. PubMed ID: 22847941
[TBL] [Abstract][Full Text] [Related]
9. Gingival fibroblasts and medication-related osteonecrosis of the jaw: Results by real-time and wound healing in vitro assays.
Yuan A; Munz A; Reinert S; Hoefert S
J Craniomaxillofac Surg; 2019 Sep; 47(9):1464-1474. PubMed ID: 31327558
[TBL] [Abstract][Full Text] [Related]
10. Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro.
Jung J; Park JS; Righesso L; Pabst AM; Al-Nawas B; Kwon YD; Walter C
Clin Oral Investig; 2018 Sep; 22(7):2527-2534. PubMed ID: 29388023
[TBL] [Abstract][Full Text] [Related]
11. Geranylgeraniol reverses alendronate-induced MC3T3 cell cytotoxicity and alteration of osteoblast function via cell cytoskeletal maintenance.
Patntirapong S; Korjai N; Matchimapiro M; Sungkaruk P; Suthamporn Y
J Oral Pathol Med; 2021 Feb; 50(2):191-199. PubMed ID: 33164239
[TBL] [Abstract][Full Text] [Related]
12. Serial administration of rhBMP-2 and alendronate enhances the differentiation of osteoblasts.
Kim SH; Choi HJ; Yoon DS; Son CN
Int J Rheum Dis; 2021 Oct; 24(10):1266-1272. PubMed ID: 34324274
[TBL] [Abstract][Full Text] [Related]
13.
Cho TH; Kim IS; Lee B; Park SN; Ko JH; Hwang SJ
Tissue Eng Part A; 2017 Dec; 23(23-24):1343-1360. PubMed ID: 28457207
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Açil Y; Arndt ML; Gülses A; Wieker H; Naujokat H; Ayna M; Wiltfang J
J Craniomaxillofac Surg; 2018 Apr; 46(4):538-546. PubMed ID: 29454604
[TBL] [Abstract][Full Text] [Related]
15. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
16. Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts.
Giannasi C; Niada S; Farronato D; Lombardi G; Manfredi B; Farronato G; Brini AT
Int J Med Sci; 2019; 16(1):23-32. PubMed ID: 30662325
[TBL] [Abstract][Full Text] [Related]
17. Vascular response to stress: Protective action of the bisphosphonate alendronate.
Cutini PH; Campelo AE; Massheimer VL
Vasc Med; 2022 Oct; 27(5):425-432. PubMed ID: 35879908
[TBL] [Abstract][Full Text] [Related]
18. Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice.
Tsuboi K; Hasegawa T; Yamamoto T; Sasaki M; Hongo H; de Freitas PH; Shimizu T; Takahata M; Oda K; Michigami T; Li M; Kitagawa Y; Amizuka N
Histochem Cell Biol; 2016 Sep; 146(3):337-50. PubMed ID: 27235014
[TBL] [Abstract][Full Text] [Related]
19. The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.
Açil Y; Möller B; Niehoff P; Rachko K; Gassling V; Wiltfang J; Simon MJ
J Craniomaxillofac Surg; 2012 Dec; 40(8):e229-35. PubMed ID: 22082730
[TBL] [Abstract][Full Text] [Related]
20. Vascular action of bisphosphonates: In vitro effect of alendronate on the regulation of cellular events involved in vessel pathogenesis.
Cutini PH; Rauschemberger MB; Sandoval MJ; Massheimer VL
J Mol Cell Cardiol; 2016 Nov; 100():83-92. PubMed ID: 27705747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]